These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 5109265)

  • 1. [Inhibition of gastric motility by rectal administration of hyoscine-N-butylbromide].
    Schmid E; Wagner T; Ritter U
    Arzneimittelforschung; 1971 Jun; 21(6):813-5. PubMed ID: 5109265
    [No Abstract]   [Full Text] [Related]  

  • 2. [Testing of orally administered spasmolytics demonstrated by the effect of hyoscine-N-butylbromide on gastric motility].
    Schmid E; Bleichert A; Uberla K; Ritter U; Fehlhaber E
    Arzneimittelforschung; 1968 Nov; 18(11):1449-53. PubMed ID: 4885158
    [No Abstract]   [Full Text] [Related]  

  • 3. [Effect of rectally applied hyoscin-N-butylbromide on small intestine motility].
    Schmid E; Ritter U
    Arzneimittelforschung; 1972 Dec; 22(12):2149. PubMed ID: 4679187
    [No Abstract]   [Full Text] [Related]  

  • 4. The effect of prifinium bromide (1,1-diethyl-3-(diphenylmethylene)-2-methylpyrrolidium bromide) on the gastric antral motility in man.
    Kihara T; Ishihara Y; Ota A
    Arzneimittelforschung; 1970 Jun; 20(6):762-7. PubMed ID: 5468889
    [No Abstract]   [Full Text] [Related]  

  • 5. [Inhibition of small intestine motility by orally administered hyoscine-N-butylbromide].
    Schmid E; Bleichert A; Kitzing J; Ritter U
    Arzneimittelforschung; 1969 Jun; 19(6):998-9. PubMed ID: 5820047
    [No Abstract]   [Full Text] [Related]  

  • 6. [On the differences of effect of atropine, scopolamine and some of their quaternary derivatives after subcutaneous and enteral administration with special reference to scopolamine-n-butylbromide].
    Bauer R; Gross E; Scarselli V; Stockhaus K; Wick H
    Arzneimittelforschung; 1968 Sep; 18(9):1132-7. PubMed ID: 5755927
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of antispasmodic drugs on colonic motility. Part I: Laboratory study of the dog.
    Sasaki D; Kido A; Yoshida Y
    Int J Clin Pharmacol Ther Toxicol; 1984 Jul; 22(7):333-7. PubMed ID: 6147311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of hyoscine in upper gastrointestinal tract endoscopy.
    Steger AC; Galland RB; Murray JK; Spencer J
    Am J Gastroenterol; 1986 Jul; 81(7):615. PubMed ID: 3717131
    [No Abstract]   [Full Text] [Related]  

  • 9. [Electrogastroenterographic control of the digestive effects of N-butyl hyoscine bromide].
    Martin A; Thillier JL; Moline J; Levet E; Quentin JC
    Therapie; 1972; 27(3):457-63. PubMed ID: 4655210
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of hyoscine butylbromide on gut motility.
    Guignard JP; Herxheimer A; Greenwood RM
    Clin Pharmacol Ther; 1968; 9(6):745-8. PubMed ID: 5721977
    [No Abstract]   [Full Text] [Related]  

  • 11. [Sonographic study of the effect of hyoscin-N-butylbromide on cholecystokinin stimulated gallbladder motility].
    Wagner T; Botzler R; Ritter U
    Z Gastroenterol; 1984 Jun; 22(6):305-10. PubMed ID: 6464523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blind comparative study of the inhibitory effect of intraduodenally administered hyoscine-N-butylbromide on human duodenal motility.
    Miyoshi A; Suyama T; Kawamura I
    J Int Med Res; 1977; 5(4):223-32. PubMed ID: 328327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral hyoscine butylbromide does not alter the pattern of small intestinal motor activity.
    Thompson DG; Wingate DL
    Br J Pharmacol; 1981 Apr; 72(4):685-7. PubMed ID: 7284686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of gastric peristalsis inhibition by scopolamine butylbromide and glucagon: evaluation by electrogastrography and analysis of heart rate variability.
    Katoh K; Nomura M; Iga A; Hiasa A; Uehara K; Harada K; Nakaya Y; Ito S
    J Gastroenterol; 2003; 38(7):629-35. PubMed ID: 12898354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The gastrointestinal absorption and the excretion of H3-butylscopolamine (hyoscine butylbromide) in man.
    Hellström K; Rosén A; Söderlund K
    Scand J Gastroenterol; 1970; 5(7):585-92. PubMed ID: 5474428
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of hyoscine N-butylbromide on gastroesophageal reflux in normal subjects and patients with gastroesophageal reflux disease.
    Ciccaglione AF; Grossi L; Cappello G; Malatesta MG; Ferri A; Toracchio S; Marzio L
    Am J Gastroenterol; 2001 Aug; 96(8):2306-11. PubMed ID: 11519531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the anti-peristaltic effect of glucagon and hyoscine on the small bowel: comparison of intravenous and intramuscular drug administration.
    Gutzeit A; Binkert CA; Koh DM; Hergan K; von Weymarn C; Graf N; Patak MA; Roos JE; Horstmann M; Kos S; Hungerbühler S; Froehlich JM
    Eur Radiol; 2012 Jun; 22(6):1186-94. PubMed ID: 22270141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent duodenal manometric and impedance recording to evaluate the effects of hyoscine on motility and flow events, glucose absorption, and incretin release.
    Chaikomin R; Wu KL; Doran S; Jones KL; Smout AJ; Renooij W; Holloway RH; Meyer JH; Horowitz M; Rayner CK
    Am J Physiol Gastrointest Liver Physiol; 2007 Apr; 292(4):G1099-104. PubMed ID: 17204542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A clinical trial of hyoscine-N-butylbromide in labour.
    Roopnarinesingh S; Crichlow R
    West Indian Med J; 1974 Mar; 23(1):22-4. PubMed ID: 4456816
    [No Abstract]   [Full Text] [Related]  

  • 20. [Use of salazopyridazine in suppositories in chronic colitis].
    Nogaller AM; Averina TK
    Klin Med (Mosk); 1982 Apr; 60(4):43-7. PubMed ID: 6124655
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.